

4月7日 星期三

- 分類廣告請預付廣告費，如中途停刊者，恕不退還費用。
- 刊登一個月以下者，廣告均不得改稿，需改稿每份酌收費用 5 元
- 本報接受 VISA 及 MASTER 信用卡付款，如電話 (Tel) 或傳真 (Fax) 訂稿委刊，請告知信用卡號碼、姓名、有效期限、CVV 號 / ZIP code 並附號，其訂稿如有錯誤由客戶自行負責，恕不補登。
- 截稿時間：星期一至五 3:00pm，**平時 / 周六日請微信: AD7133021553**
- 截稿或之前訂稿，其稿將在第二天刊出。

100  Restaurant Hiring
餐館服務

***中餐快餐店**
誠請打雜
位Humble區
意者請電:
917-291-5895

***高薪 聘請 炒鍋, 油爐, 企檯**
餐館 近 **Puerto Rico** 波多離各島,
誠聘 ●有經驗炒鍋 (Cook)
●有經驗油爐 (Deep Fry)
●有經驗企檯 (Waiter/Waitress)
以上**新僱**, 包住宿. 有意者請電:
340-344-5656 Stephen 洽

Haidilao Hot Pot
海底撈火鍋

海底撈 Katy 店現招聘如下崗位
(要求: 合法身份, 全額報稅)

1. 全職庫管 1 名: 能進行基本英文交流
2. 經理助理: 中英文流利, 有人事或財務相關經驗
3. 服務員, 門迎: 培訓通過後有小費, 英文流利, 有餐飲經驗優先
4. 後堂領班, 炒鍋, 備餐, 切肉: 有廚房經驗優先考慮

聯繫電話: Mandy: **949-520-0368** / Cathy: **510-575-9777**
投遞簡歷至: **Katyhaidilao@gmail.com**

黃金茶寮, 新優
樓面: 請 周末帶位
及傳餐人員
廚房: 請 抓碼, 炒鍋.
點心部: 請
有經驗做點心人員
2pm 後電或親臨舊店:
281-495-1688
10600 Bellaire #105

Buffet店請人
距中國城8分鐘
Buffet店
誠請 全工 / 半工
熟手企台, 帶位
意者請電:
713-789-0845

***日本餐館請人**
有經驗 經理、企檯
壽司師傅、炒鍋。
需有工卡,新水面談。
有意者請電:
832-715-4753
832-969-5588

中日快餐店
位於 I-10 Memorial
99 大華附近
● **Sushi Man**
(壽司幫手)
● **Kitchen Helper**
(廚房幫手)
☎: 832-380-0247

***美式炸蝦店**
位 Pasadena 區,
房租 2000.
營業額 \$23000.
因店主急需回國出售.
有意者請電: 非誠勿擾
833 388 3112

餐館店鋪轉讓
位於塘城6號，
周圍有大型老美超市
跟華人超市，
人流量大，1千多遲，
生意穩定，
適合家庭經營，
有意者請電：
713-775-3898

Burger Shop For Sale
Near Downtown Houston
\$55,000, Cheap rent
Includes all equipment & easy to learn
Text/call/voicemail: **832-212-6049**
漢堡店出售,易經營. 近休士頓市中心
租金低,含設備,售價5萬5.請傳訊息或留言

糖城新餐館出租,機會難得!!!
Good opportunity to own a fairly new restaurant in SugarLand. Offer 50% down payment option with owner finance. (No real estate involved). 4 years remaining lease plus 5 years option to renew. 業主可提供50%首付貸款。(不含房地產)。剩餘4年的租約,加上5年的續簽選擇。
誠意者請電 Suzie : **713-261-8255**

房地產租售



Sale/Rent



按摩服務
Massage Service



1000
Massage Service
按摩服務

極品 Baby! 粉嫩少女
高顏值
832-380-1539



Massage School
按摩學校招生中

HFE 正規專業按摩學校招生
英文: **713-528-2097**
中文: **832-231-5279**
地址: **4141 Southwest Fwy #510 Houston, TX 77027**
● 德州立案 500 小時按摩課程培訓 (MS0098)
● 全期 5 個月課程。
● 有專業按摩執照老師, 中英文授課。
● 學費有優惠, 不另收額外費用。
● 聯邦按摩考試 MBLEX 衝刺班。
● 聯邦按摩考試加強班 100% 通過率。
● 按摩執照更新服務。
● 免費按摩英文課程。
Call Today 儘速連絡, 或至網站查閱訊息
www.HFEmassageschool.com

凱悅
實惠的價格
輕鬆的享受
832-359-6141

妙齡網紅, 丰乳翹臀
真實日本 AV 女優 + 高端洋妹
832-821-6686

**** 高級 SPA ****
漂亮氣質東方美女
早 9 點 - 晚 12 點
休斯頓中國城. 歡迎電話預約:
832-988-7118



Massage School
按摩學校招生中

1000 HIRING for Massage
按摩請人

招男按摩員
中國足浴
現招男按摩員
月入 \$5000
要求有力氣, 能吃苦
生手可教。
有意者請電:
832-293-5537

按摩請人
45 南 36 出口,
6 年正規床店請人,
全職 6 天, 兼職 3-5 天
可住店, 能做大力,
有萊森經驗者優先。
832-417-4410
(做黃勿擾)

韓式大型 SPA
休士頓, Katy
Westgreen & Kingsland
誠招能報稅, 有執照的
按摩師 (男女不限)。
大費高, 小費好。
絕對色免。聯系電話:
281-743-6613

海邊高端 SPA
長期招聘
兼職全職按摩人員
男女均可, 不會的可教
只需要你有一顆
願意學習的心。
有意者請聯系:
636-399-7438

休斯頓好區
正規床腳店
招女按摩師, 有工卡,
能報稅, 大費五五分
成, 每天日結工資,
有執照者優先,
無車者住宿條件優越。
有意者請電:
346-247-6440

1000 按摩請人
HIRING for Massage

1000 教授英文 & 西班牙文
本地美國人, 資深英語家庭教師, 教授日常美語
會話、商業及旅遊用語, 個人或集體均可。
*** 協助通過公民考試及移民局面試 ***
skype: david.b.browning / Wechat: Teresina1only
832-788-3383 281-587-6912 布朗寧
5338 Beechnut St. Houston, TX 77096
http://davidbrowning.trustab.org

美南新聞電子報
e-Paper

入籍班招生

公民入籍考試輔導班 保證通過
* 由專業入籍考試輔導老師一對一教學輔導
* 提供最新入籍考試基本試題, 模擬考題, 仿真練習, 讓您 100% 通過
* VIP 級別輔導, 時間靈活, 循環輔導, 依照學員的基礎量身定制
* 面試由專業律師陪同
歡迎電話諮詢: **713-815-5011 / 832-279-7772**
10700 Richmond Ave, STE 230, Houston, TX 77042

1000 駕駛學校
Driving School

美南駕校
疫情期間有中文網絡筆試課, 取消罰單課, 保證證書。
美南駕校是官方指定考點, 天天有路考。旅遊簽證等各種簽證
可以考駕照。青少年班隨時上課。
● 成人筆試班: 周二, 六 10am-4pm
● 取消罰單安全班: 周二, 六有課
7001 Corporate Dr #203 832-277-7226 王教練

1000 駕駛學校
Driving School

DPS 指定 王朝駕校 路考第三考場
DPS 路試考官, 全權下放至百利駕校的教練路試。
在本校一天可完成筆試, 取得 permit 後可安排路考, 不用排隊等 30 天
筆試班: 每星期一至六上課, 務必預約。
路考班: 務必預約。 考路試, 務必預約。
安全班: 隨時開課。 開課, 務必預約。
電話: **832-633-5555** 周師傅 **832-983-9509** Tom 發哥

W-2 TAX 報稅
報稅服務

******* 報稅 *******
● 報個人稅, 公司稅
● 公司做帳
地址: 美國財富會計樓
6348 Corporate Dr, Houston, TX 77036
打電話或短信: **917-378-5316**

房產經紀
Realtor

房地產經紀人
Kate Zhang
● 個人房屋買賣
● 商業房產買賣
微信: **15042558967**
電/短信: **917-378-5316**

Gun License
申請帶槍執照

德州帶槍執照
中國城軍火庫
可在全美 38 州攜帶
全課程半天完成 \$100
(外州駕照可申請)
各式槍枝買賣/交換
9896 Bellaire #G1
(黃金廣場內)
281-236-4723

譯
口譯服務

專業口譯
移民、醫療、商業
中英流利, 收費合理
832-877-0828
(陸克) 微博:
L8327792838

各種翻譯

美華翻譯中心 M&H Translation Services
● 專業翻譯各種學歷證書, 成績單, 結婚, 離婚, 出生, 死亡證書。
● 各種戶籍, 房產, 銀行證明 ● 法律, 經濟, 財務等專業文件及口譯,
代辦公證認證。● 30 多年翻譯經驗, 得到美國 & 中國政府機構認可接受。
價格優惠, 專業迅速。 電話: **713-414-3115**
電郵: **service@ustranslator.com davidwon1025@hotmail.com**
Http://www.ustranslator.com
Member of the American Translators Association

800 狗狗寵物美容
Pet Grooming

JuJu's 寵物美容
美國專業資格認證
手工剪毛, 寵物託管 \$20
精心照顧, 收費合理
近 Richmond/休斯頓
281-818-8809
281-496-7878
12624 Briar Forest

千里姻緣
登廣告專線: **281-983-8151**

*** 男士徵婚 ***
美國公民, 華裔, 身體健康,
收入穩定, 能講中英文,
誠尋 45 歲以下, 溫柔賢惠女士
先友後婚。非誠勿擾。
誠意者請短訊: **713-494-5236**

*** 男士征婚 ***
69 歲, 喪偶, 身高 1.74 米,
身體健康, 性格開朗,
誠尋有意組建家庭的有緣中國女士。
非誠勿擾, 請短信: **281-236-2626**

*** 為子徵婚 ***
36 歲男, 有房, 生存能力超強,
身高 188, 基本優良, 誠待心地善良,
寬容大度, 強弱皆可,
20-30 歲精實優良女士。先友後婚。
意者請電: **832-969-5083** 李

800 機場接送
Transportation

北夏接送服務
機場, 碼頭, 一切接送
誠信可靠, 安全準時。
保證最低價。有 4 人 7 人座服務
832-382-5645

FOR SALE
車輛買賣
Car for sale

專收購舊車壞車
舊、壞車
動或不動
一律高價收購
中英粵越。電話:
713-482-9267

800 汽車
保養修理
Auto Repair

李氏修車行/汽車買賣
換機油 \$18.99 年檢 \$25 “銀金部” 多有折扣
專修本國車, 進口車, 引擎系統, 剎車系統, 變速器, 電路
銀金噴漆, 修理 代辦一切保險理賠, 24 小時拖車服務。
Lee Enterprises Complete Auto Repair
11830 Beechnut St. Houston, TX 77072 / Kirkwood
電: **281-575-7221** (中英越) 手機: **832-622-7134**
6 天營業 週一至週六: 9 點 - 6 點

床墊世界
腰酸背痛, 輾轉難眠? 夢想一覺睡到自然醒?
還好有 30 多年老字號的床墊世界, 專賣各種超硬
實木板床墊和彈簧床墊。美國生產, 質量最優,
價格最平, 款式最齊, 市內免費送貨。
※ 另有廠家直銷各式家具及自動清洗抽油煙機。
請電: **713-777-1188** (近 59 離中國城 5 分鐘)
6121 Hillcroft Ave, Ste M1, Houston, TX 77081
www.mattressworldhouston.com

700 修理業務
Remodeling

蘇揚建築裝潢
價格公道, 質量保證
房屋, 廚房, 衛生間裝修
地板, 磁磚, 大理石面安裝
電氣, 煤氣, 鐵欄安裝維修
車庫門, 自動門安裝維修
水電, 空調, 安裝維修
832-607-7861 張
● 誠請裝修工人

榮盛裝修
商業住宅, 水電木工,
地磚地板, 浴室櫥櫃,
內外油漆, 大理石安裝,
小修小補。
質量第一, 誠信價廉!
請電: Sam 劉
832-60



CLASSY 殺蟲專家
Classy Pest Control 提供專業的殺蟲服務
包括住家及商業地區，
讓您擺脫蟻、蜘蛛、白蟻等的困擾
本公司提供免費的估價。
34年專業經驗。專業白蟻檢測及殺蟲服務。
電話(英): **281-437-4329, 713-516-1747**
(中文): **346-252-9893**



PN Pro Glasses 門窗公司
品質保證+安全保證+價格便宜保證
Commercial & Residential 商業/住宅
Shower Door, Window Glass
Mirror Wall, Furniture Glass
浴缸,浴室落地玻璃門,住家辦公大樓大門玻璃
一般牆上及臥室大型鏡子,傢具台面玻璃
請英文/越語: **346-561-2430**



專業砍樹
華人經營,專業砍樹,
修理樹枝,挖樹根,栽花,
種樹,鋪草皮,各種場地
清理,修建籬笆圍牆,
清理水溝,清理垃圾,排後院
積水,搬運及雜活。
全市最低價100元起
832-969-5083 李



籬笆 Fence
專業維修,重建,新建,
各型籬笆,范士,圍欄,
圍牆,價格優惠,
10年質量保證,
完工後滿意付款,
全市最低價,150元起。
832-969-5083 李



庭園美化
7.00
專業維修,重建,新建,
各型籬笆,范士,圍欄,
圍牆,價格優惠,
10年質量保證,
完工後滿意付款,
全市最低價,150元起。
832-969-5083 李



敦煌地板
地板 \$1.89/呎 & up
地毯、磁磚、花崗石
內外油漆,廚浴更新
832-353-6900
9889 Bellaire #B-24-C
(大中華超市旁邊)



地毯清潔
地毯清潔
Carpet cleaning



房屋理賠
房屋理賠
Claims Service



房屋理賠
房屋理賠
Claims Service



房屋理賠
房屋理賠
Claims Service



房屋理賠
房屋理賠
Claims Service



房屋理賠
房屋理賠
Claims Service



房屋理賠
房屋理賠
Claims Service



房屋理賠
房屋理賠
Claims Service



房屋理賠
房屋理賠
Claims Service



房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service

房屋理賠
房屋理賠
Claims Service



If you would like to share news or information with our readers, please send the unique stories, business

news organization events, and school news to us including your name and phone number in case more information is needed.

For news and information consideration, please send to News@scdaily.com or contact
John Robbins 281-965-6390
Jun Gai 281-498-4310

Publisher: Wea H. Lee
President: Catherine Lee
Editor: John Robbins

Address: 11122 Bellaire Blvd., Houston, TX 77072
E-mail: News@scdaily.com



Inside C2

Southern DAILY

Make Today Different

Southern Daily News is published by Southern News Group Daily

Wednesday, April 07, 2021|

Bezos, Musk top Forbes' record-setting billionaire list

(Reuters) - Forbes' annual world's billionaires list includes a record-breaking 2,755 billionaires, with Amazon.com Inc founder Jeff Bezos topping it for the fourth consecutive year, the media company said on Tuesday.

The ranks of the ultra-wealthy are expanding after a year in which the coronavirus pandemic upended world economies and threatened the livelihoods of people across the globe.

This year's billionaires are worth a combined \$13.1 trillion, up from \$8 trillion last year, Forbes said. "The very, very rich got very, very richer," said Forbes' Chief Content Officer Randall Lane, in an interview with Reuters Video News.

Tesla Chief Executive Elon Musk jumped into second spot on the list, up from 31st last year. Bernard Arnault, chief executive of luxury goods firm LVMH, Microsoft founder Bill Gates and Facebook Chief Executive Mark Zuckerberg round out the top five of the world's richest billionaires. Investor and business tycoon Warren Buffett fell out of the top five for the first time in over two decades, as tech executives dominate the Forbes rankings.

This year's list has 493 newcomers, including Whitney Wolfe Herd, chief executive of dating app Bumble, which went public this year.



UNIVERSITY of HOUSTON MASTER'S DEGREE IN WORLD CULTURES AND LITERATURES WITH A CONCENTRATION IN CHINESE STUDIES

Department of Modern and Classical Languages, UH

Innovative Approach

Our innovative approach includes a wide range of paths to meet individual academic and career interests. The program pays special attention to students' needs by offering flexibility in their curriculum, learning progress, and career goals. The program focuses on teaching Chinese as a second language with an emphasis on individualized career development. It seeks to fit the schedules and learning paces of both aspiring and in-service teachers. Scholarships are available! Please check our webpage: <http://www.uh.edu/class/mcl/wcl/masters/index.php>

Distinctive Features

Accommodates curriculum and coursework to match students' needs and career interests with faculty expertise in applied linguistics, Chinese Literature, Chinese linguistics, language education, and world cultural

- studies.
- Offers online courses that integrate in-depth second language acquisition studies and innovative classroom instruction.
- Prepares students to creatively develop curriculum and effectively implement instruction in a student-centered environment.
- Provides hands-on experience in designing lesson plans, conducting class activities, and creating a supportive classroom for high language proficiency levels.
- Enhances K-12 teachers' skill set with current education theories and research for reflection and peer learning.
- Expands technology-based skills in teaching and learning.
- The scholarship, Excellence in Graduate Chinese Studies, are available.

Program Course Components
The program provides maximal flexibility and a solid foundation.

- Two courses (6 hrs.) for world cultural studies:
WCL 6351 Frames of Modernity I.
WCL 6352 Frames of Modernity II or WCL 6353 Frames of Modernity III.
- One course (3 hrs.) in 6000-level history related to Chinese or Asian culture and language.
- Five courses (15 hrs.) selected from 6000-level courses related to teaching Chinese as a second language. Topics include studies of second language acquisition, application of second language acquisition theories to Chinese language education, Chinese literature, linguistics, pedagogical

grammar, teaching principles and models, theme-based curriculum, task-based instruction, creative use of teaching materials, language assessment, and integrating technology into the teaching of language and culture.

- Two elective courses (6 hrs.) to fit students' career interests taught in MCL or other departments.

Apply for the program at <http://www.uh.edu/class/mcl/wcl/docs/WCL%20MA%20Application%20Form.pdf>
Deadlines for application: November 1 for Spring admission and April 15 for Fall admission.

UNIVERSITY of HOUSTON | MCL

敬請關注我們的新媒體賬號 Follow us on social media



Southern News
美南新聞



公共頁
美南網



今日頭條
美國美南網



抖音
美國美南網



美國美南網



Facebook Page:
Southern News
美南新聞



Tik Tok ID:
Southern News
Group



Instagram ID:
Southern News

WEA LEE'S GLOBAL NOTES

CORONAVIRUS DIARY

04/06/2021



Wea H. Lee
Wealee@scdaily.com

Chairman of International District Houston Texas

Publisher Southern Daily Wea H. Lee

Southern News Group Chairman / CEO
Chairman of International Trade & Culture Center
Republic of Guiana Honorary consul at Houston Texas



We Are The Nation Of Immigrants



Today we really appreciate all the leaders from the different communities that have come to support the ITC Community Resource Center. This project will open the door for all of us and build a bridge between our community and government.

Since the middle of the 1980's many new immigrants and students came to America including many from China and other Asian countries. According to the

latest census, there are over twenty million Asians in the United States with five million of them being Chinese. They were also the earliest immigrants from Asia.

After World War II many immigrants made very outstanding contributions to America's economy and we have become a superpower ever since then. Even today, companies like Google, Zoom and other top high-tech companies are led by

immigrants.

We strongly suggest to President Biden to open the door for newcomers. For those students who get their masters, doctorate or PhD degrees, we should issue them permanent residence cards so they can stay to continue with their life's work here in the U.S.

Many people in this country are against a strong immigration policy simply because of their political interest.

After all, we are the nation of immigrants. If we want to keep strong in the future, we need more new blood to build our nation.



Southern DAILY Make Today Different

Editor's Choice



U.S. President Joe Biden stands to deliver his remarks on the tradition of Easter, next to first lady Jill Biden holding a flower and a person wearing an Easter Bunny costume at the Blue Room Balcony of the White House in Washington. REUTERS/Kevin...



Anti-coup protesters burn a Chinese flag in Yangon, Myanmar. REUTERS/Stringer



Norah Miller has her picture taken by her friend Emma McCain as they visit the 50 acres of Ranunculus flowers at "The Flower Fields" in Carlsbad, California. REUTERS/Mike Blake



A view of the fans and the stands during the second inning of the game between the Texas Rangers and the Toronto Blue Jays at Globe Life Field in Arlington, Texas. Jerome Miron-USA



Minneapolis Police Chief Medaria Arradondo answers questions on the sixth day of the trial of former Minneapolis police officer Derek Chauvin (L) for second-degree murder, third-degree murder and second-degree manslaughter in the death of George Floyd in Minneapolis, Minnesota. REUTERS/Jane Rosenberg



People attend a vigil for rapper DMX outside a hospital in White Plains, New York. REUTERS/David 'Dee' Delgado

How COVID-19 Can Be Crippled By An Age-Old Blood Thinner



The blood thinner heparin could be used to trap SARS-CoV-2, effectively neutralizing the virus before it can infect healthy cells, a Rensselaer Polytechnic Institute team said. (Maksim Tkachenko/iStock/Getty Images Plus)

Compiled And Edited By John T. Robbins, Southern Daily Editor

Much of the effort to develop remedies and vaccines to fight COVID-19 has centered around the spike protein that the culprit virus, SARS-CoV-2, uses to invade healthy cells. Scientists at Rensselaer Polytechnic Institute believe they've found a way to block the spike protein's ability to infect cells—and it involves a 78-year-old blood thinner.

The drug is heparin, which is widely used to treat and prevent blood clots. The RPI team discovered that SARS-CoV-2 binds tightly to heparin, making the drug a potential “decoy” that could serve as a way to neutralize the virus before it can infect healthy cells. They reported the finding (PDF) in the journal Antiviral Research. The RPI researchers made the discovery by studying gene sequencing data for SARS-CoV-2 and recognizing certain characteristics of the spike protein they believed would make it likely to bind to heparin. They tested three variants of the drug, including a non-anticoagulant formulation, against the virus, using computational modeling to define how they bound to the pathogen.



By binding to SARS-CoV-2, the blood thinner traps the virus, “which can't exist really sitting there, bound to the heparin. It'll just degrade,” explained Jonathan Dordick, Ph.D., professor of chemical and biological engineering at RPI, in an interview with FierceBiotechResearch. “There has been very rapid research that has come out in the last couple of months about the proteins on the surface of the coronavirus. Once we know their approximate location on the surface, and what the receptor is [on cells] that the virus targets, it allows us to very quickly tailor this DNA nanostructure” to COVID-19, he said. Dordick's team has developed a research proposal, which includes testing the viral trap technology in animal models of COVID-19, he added.

RPI is one of several institutions stepping up with ideas of how to take existing research and pivot it toward potential solutions to COVID-19. And these ideas are not just bubbling up in academia. Some biotech startups are taking existing antiviral discoveries—or even technologies they initially developed to address very different diseases, like cancer—and offering to deploy them toward defeating the coronavirus.

well known for his creation of synthetic heparin. Some blood thinners are already being used by physicians treating COVID-19. Demand for Bristol Myers Squibb's Eliquis skyrocketed earlier this year following reports that the drug could prevent strokes in seriously ill patients. The RPI researchers are proposing that heparin be used as a stopgap measure against COVID-19 until a vaccine is found. The drug could be delivered in an inhaled form to people who have been exposed to COVID-19, they suggested.



“This approach could be used as an early intervention to reduce the infection among people who have tested positive, but aren't yet suffering symptoms,” said lead author Linhardt in a statement. “Ultimately, we want a vaccine, but there are many ways to combat a virus, and as we've seen with HIV, with the right combination of therapies, we can control the disease until a vaccine is found.” (Courtesy <https://www.fiercebiotech.com/>)

Related

COVID-19: Bio researchers race to repurpose everything from antiviral to anticancer discoveries

Jonathan Dordick, Ph.D., and his lab mates at Rensselaer Polytechnic Institute (RPI) weren't thinking about coronaviruses when they initially developed their “viral trap,” a DNA-based nanotechnology designed to capture and kill viruses floating in the bloodstream. But as the COVID-19 pandemic started to unfold, they realized they may be able to transform their invention into a potential solution to the relentless virus—and they got to work on a plan to do so.



The rapidly growing understanding of COVID-19 has inspired several research groups to propose new methods for prevent-

ing and curing the disease. (ESB Professional/Shutterstock)

Jonathan Dordick, Ph.D., and his lab mates at Rensselaer Polytechnic Institute (RPI) weren't thinking about coronaviruses when they initially developed their “viral trap,” a DNA-based nanotechnology designed to capture and kill viruses floating in the bloodstream. But as the COVID-19 pandemic started to unfold, they realized they may be able to transform their invention into a potential solution to the relentless virus—and they got to work on a plan to do so. “We have something that can be tailored specifically to the virus,” said Dordick, professor of chemical and biological engineering at RPI, in an interview with FierceBiotechResearch. “There has been very rapid research that has come out in the last couple of months about the proteins on the surface of the coronavirus. Once we know their approximate location on the surface, and what the receptor is [on cells] that the virus targets, it allows us to very quickly tailor this DNA nanostructure” to COVID-19, he said. Dordick's team has developed a research proposal, which includes testing the viral trap technology in animal models of COVID-19, he added.

RPI is one of several institutions stepping up with ideas of how to take existing research and pivot it toward potential solutions to COVID-19. And these ideas are not just bubbling up in academia. Some biotech startups are taking existing antiviral discoveries—or even technologies they initially developed to address very different diseases, like cancer—and offering to deploy them toward defeating the coronavirus.



It may take several months or even years for these efforts to bear fruit, at which point this pandemic may have ended, but that's no deterrent, many scientists say. “We will see new viruses being passed from animals to humans again,” predicted Christian Peters, M.D., Ph.D., CEO of Pinpoint Therapeutics, in an interview with FierceBiotechResearch. Pinpoint is one of the companies that's putting plans in place to target COVID-19. “We must have an armamentarium of different drugs with different mech-

anisms so we're ready for the future that's to come,” Peters said. RPI's viral trap is adaptable to a range of viruses due to its design, Dordick explained.

The next step would be to use the same nanotechnology platform to kill the virus once it's snared in the trap. “In detecting the virus, we're also preventing it from binding to its receptor,” he said. “We showed that the DNA binds to the proteins on the surface of the dengue virus, preventing them from infecting the target cell. In that way, we can inhibit the infection process.” Dordick's team has shown that a similar approach is effective in preclinical models of influenza A and Zika virus, as well.



Researchers at the University of Pennsylvania discovered that inhibiting PPT1 slows tumor growth—a finding that led to the formation of Pinpoint, which is now optimizing PPT1 inhibitors to test in cancer. Pinpoint has received seed funding from Kairos Ventures, which in February kicked in \$1 million in debt funding to help accelerate the search for candidate drugs. Although it will take several months to complete the laboratory and animal studies needed to identify drug candidates against COVID-19, Peters believes the insights they gain will remain relevant, even if the pandemic has resolved by that time. “It's important to look not just at the anti-viral components, but also at the anti-inflammatory properties that these drugs might have.

The rapidly unfolding COVID-19 pandemic has inspired the scientific community to come up with solutions that will have the potential to save lives in the future, RPI's Dordick said. “The key question after we get through this tragedy is, ‘how will we avoid it again?’” Dordick said. “Will we have to shut everything down again, or can we have directed therapeutic development? I think we're learning the lesson that we need rapid vaccine development and rapid therapeutic development. We're going to learn an awful lot about what we can do.” (Courtesy <https://www.fiercebiotech.com/>)

What Covid Treatments Are Working And What More Is On The Horizon?



New data from a large U.K. trial added to evidence indicating plasma may not make a difference in treating Covid-19. (Photo/Alex Edelman/AFP via Getty Images)

Key Point

Some therapies that faced early questions are regaining their promise as we learn more. Others aren't, but it's important news either way.

Compiled And Edited By John T. Robbins, Southern Daily Editor

The arrival of Covid-19 vaccines has put the focus of the pandemic fight on inoculating as many people as quickly as possible. But outbreaks are still raging worldwide, with thousands of new infections every day and health systems under pressure to care for the sick, a reality that will continue for some time. Vaccine timelines also keep getting more and more stretched. With that in mind, it's a good time to take stock of where we are in treating the disease. The short answer is, there's progress but it's mixed.

For months, Gilead Sciences Inc.'s **remdesivir** and the generic steroid dexamethasone have been used on the front lines after being shown to reduce hospital stays and improve recovery speeds. Now, as we learn more about Covid-19, more treatments — including some that at first drew skepticism from physicians and scientists — are proving effective in certain circumstances. Others, such as convalescent plasma, are not. Let's take a look:

“**Toci**”: Two arthritis drugs that previously failed in treating Covid-19 — Roche Holding AG's **tocilizumab** and Sanofi-Regeneron Pharmaceuticals Inc.'s **sarilumab** — are now showing a meaningful effect in helping reduce the burden of

disease in some patients. It seems that when the drugs are used is key. The latest data comes from a trial involving patients who were treated within 24 hours of needing hospital care in an intensive care unit. The drugs reduced mortality, suggesting that seven or eight lives would be saved for each 100 people treated.



The hope is that this data will be corroborated in the U.K.'s much larger and pioneering Recovery trial, now underway, with more than 28,000 patients being treated with **toci**. This will provide the most concrete data behind the drug and will potentially enable global approvals beyond Britain.

“**Bam-bam**”: Next up are new drugs developed by Eli Lilly & Co. and Regeneron, part of a promising group of therapies called monoclonal antibodies that mimic the body's

response to infection. Lilly's **bamlanivimab**, affectionately known as “bam-bam,” was the first to gain emergency use authorization by the Food and Drug Administration. Both Lilly's and Regeneron's treatment have now been cleared for high-risk patients to help prevent hospitalization. One obstacle for adoption of these drugs has been the logistics of administering them — they need to be delivered using specialized infusion equipment. This difficulty was compounded in bam-bam's case with a confusing efficacy story and lukewarm comments about it in the Covid-19 treatment guidelines from the National Institutes of Health, resulting in doses piling up on hospital shelves. This situation may be about to change, though, given an early read from a 2,000-patient Mayo Clinic study in which the use of bam-bam was shown to reduce hospitalizations and emergency-room visits by 70%.



There are also indications of a reduction in mortality. When data from this study is published, it is likely to drive increased interest in the use of bam-bam, and possibly Regeneron's antibody treatment, too. I do still remain cautious about the broad use of these drugs because of the risk they may hasten development of resistant mutations in the virus, which may, though unlikely, also impact vaccine-induced immunity.

Plasma: Convalescent plasma, a source of hope in the early days of the pandemic, has had a lot of subsequent failures and questions about its use. While not a drug per se, it is supposed to work in a similar way as monoclonal antibodies by giving patients ready-made immunity in a bottle in the form of plasma from recovered patients that is full of antibodies to the virus. The problem with previous attempts in showing a benefit from this approach was a lack of standardization and its use at the wrong time. Then recent data from a trial in Argentina raised hopes that if you use plasma with high amounts of antibodies early enough, when the infection itself is still active, it does make a difference. Unfortunately, there's since been another setback, and this time a very serious one. The

U.K.'s aforementioned Recovery trial has been comparing Regeneron's antibody treatment and convalescent plasma to standard care without those treatments in a very large patient group, making the data and its statistical analysis very robust.



Findings released Friday from the trial showed no difference in the mortality of those receiving plasma and those on placebo. We still need to see the data in published form to be able to judge if there were any other potential explanations for the outcome. But if the result is unequivocal, it at least means there will be no more time and money wasted treating patients with an ineffective therapy that carries some risks. In a way, the negative outcome is still a step forward in sharpening treatments of Covid-19.

Once A Relic Of Medical History, Radiation Emerges As An Intriguing — And Controversial — Treatment For Covid-19

The idea of low-dose radiation as therapy had long been dismissed in favor of more modern treatments. That all changed when Covid-19 snowballed into a crisis, fueling fresh interest in anything that might ease the devastating cases of pneumonia in some patients. At least 52,000 of the more than 135,000 deaths due to Covid-19 in the U.S. have involved pneumonia, according to federal health data.

There are currently at least a dozen trials worldwide testing low-dose radiation therapy, or LDRT, as a treatment for pneumonia related to Covid-19, some spurred by the same historical data Calabrese and colleagues scoured years ago. The theory: Targeted radiation to the lungs will halt the out-of-control inflammation responsible for the devastating pneumonia that bookends the course of some Covid-19 patients.

General Photographic Agency/Getty Images

But the revived interest in radiotherapy has sparked a debate among physicians and researchers, who are divided on whether the idea is even ready for test-driving in clinical trials. With little known about the way LDRT works on inflamed lungs, some experts say it might

exacerbate respiratory damage, while introducing the additional risk of cancer. Others say patients participating in the trials may suffer by missing out on more promising treatments.

On the other side, though, are experts who say there's a clear and urgent need for Covid-19 treatments that work, particularly for cases that become severe. Antibiotics can help treat cases of pneumonia from bacterial infections, but not those caused by viruses. Those experts argue compelling historical data gives LDRT a promising head start.

“It seems to be such an almost emotional topic,” said Dörthe Schaeue, a radiation oncologist at UCLA, on the debate raging over LDRT. “You get two extremes on the spectrum and the truth is probably somewhere in the middle, where you have to consider all the pluses and minuses.”



The new wave of low-dose radiation trials are registered at academic centers and hospitals around the world, including in Italy, Spain, Iran, India, and the U.S. The studies are recruiting anywhere from five to 106 Covid-19 patients with pneumonia, and half require participants to be at least 40 years of age.

Arnab Chakravarti, chair of Ohio State's radiation and oncology department, is spearheading two of the four LDRT trials in the U.S. The first trial, PREVENT, will enroll around 100 oxygen-dependent Covid-19 patients at up to 20 hospitals around the country. The second trial, VENTED, is limited to Ohio State, where it will recruit 24 critically-ill patients who require ventilator support. Unlike PREVENT, VENTED is open to participants as young as 18.

The end of the pandemic may be in sight, assuming we can control infections and the development of new variants, but it's still many months away. Fortunately, the more we learn, the better we know which treatments are helpful and how to use them. The arsenal is growing. We can use all the help we can get. (Courtesy Bloomberg.com and <https://www.statnews.com/>)

美南國際電視15.3 《美南時事通》 德州成年人疫苗開打 輝瑞 莫德那 強生 到底該打哪種？

（本報記者黃梅子）德州從3月29日起已經開放給所有的成年人打新冠疫苗，有很多人急於打疫苗，但也有部分民眾認為疫苗研發時間太短、不安全，擔心自己變成小白鼠。三種新冠疫苗在美國獲準上市，人們開始挑剔要注射哪一種。

這三種疫苗都被證明在預防新冠病毒，避免因重癥導致住院和死亡方面有效。美國衛生官員表示，最好的疫苗就是你能得到的那種。儘管如此，人們似乎越來越傾向於選擇輝瑞（Pfizer）和莫德納（Moderna），而不是強生（Johnson & Johnson）。

有些人說，他們寧願推遲接種，也不願選擇強生。目前，衛生官員們正努力讓美國人放心，任何經過授權的疫苗都是不錯的選擇。今年2月，美國監管機構正式批准了強生的單針疫苗，這是最新獲批的疫苗。輝瑞和莫德納的疫苗使用了新的信使核糖核酸（mRNA）疫苗技術，需要注射兩針，而強生疫苗用的是普通感冒病毒，這種病毒已經滅活。它可以安全攜帶部分冠狀病毒的遺傳密碼進入人體，足以讓身體意識到威脅，然後學會抗擊冠狀病毒。美國總統拜登對該疫苗表現出信心。本月，他宣布美國將訂購1億劑強生疫苗，令美國人可獲得的劑量增加壹倍。

美國國家過敏和傳染病研究所（National Institute of Allergy and Infectious Diseases）所長安東尼·福奇（Anthony Fauci）博士表示，美國所有可用疫苗都是優質疫苗，並強調強生疫苗“不是較差的疫苗”。

專家表示，人們的擔憂源於臨床試驗公布的療效數據，但這些數據並不代表全部事實。這三種疫苗都能100%防止因感染病毒而導



致入院和死亡。輝瑞和莫德納的藥物也在最新、更具傳染性的病毒變體廣泛傳播之前進行了測試，在臨床試驗中發揮了作用。強生疫苗的另壹個優點是，它是美國唯壹壹種可獲得的單針疫苗。

壹般疫苗從研發到推出市場需時十年，但

新冠疫苗卻在壹年內就面世，到底哪些程序加速了？強生疫苗的分發可能更方便，特別是在壹些貧困地區或農村等難以到達的地方。但也有人擔心，僅向這些地區運送疫苗可能會令強生背負更多惡名。

強生並不是唯壹面對質疑的疫苗。由於公

眾對血液凝塊表示擔憂，美國正在考慮批准牛津-阿斯利康（Oxford-AstraZeneca）已經在十幾個歐洲國家暫停使用。歐盟藥品監管機構隨後表示，這種疫苗“安全有效”，德國、法國、意大利和西班牙也表示，他們將恢復使用這種疫苗。

請看《美南時事通》主持人段娜和 哈裏斯縣衛生署 Leann Liu 醫師談德州成年人疫苗開打，輝瑞、莫德那、強生，到底該打哪種疫苗？

請關注美南國際電視15.3頻道《美南時事通》，也可以通過iTalkBB平臺收看。美南新聞網站 scdaily.com，也可以在 youtube 上搜索 Stv15.3 Houston，訂閱美南新聞頻道，隨時收看美南國際電視的節目。



世界華人工商婦女企管協會美南分會 2021 線上會長交接典禮記盛（中）



世華副總會長陳玲華代表北美洲所有分會負責人致賀詞。



世華名譽總會長劉珊綺致詞。



介紹2020五月份響應亞裔美國人致敬第一線英雄活動。



洪良冰會長（中）率領理事群致詞。



介紹2020六月份僑教中心前廣場發送口罩活動。



洪良冰會長（左一）將會長重任交給新任會長孫玉玟（右一），而由世華名譽總會長黎淑瑛（右二），僑教中心陳奕芳主任（左二）主持監交。



世華名譽總會長黎淑瑛（左）頒發水晶獎座給孫玉玟會長（右）。



介紹36年來世華歷屆會長。



介紹36年來世華歷屆會長。



介紹2020年三月份贊助See to Succeed婦女論壇及參加北德州分會年會。



洪良冰會長介紹2020年十月份國慶返國致敬團授旗典禮。